Objectives: To determine the effects of Phloroglucinol in acceleration of labour and its adverse effects on mother and foetus.
Methods: A double blind randomized, placebo controlled trial was conducted on 100 patients in active phase of uncomplicated labour selected by convenient sampling. Patients were given Phloroglucinol or Placebo (distilled water) intravenously. Progress of labour was plotted on Partogram. Any adverse effects of the drug on mother and fetus were noted. Student's t-test was applied for statistical analysis.
Results: In patients receiving Phloroglucinol there was a mean 34% reduction in duration of 1st stage of labour and a mean 23% reduction in 2nd stage as compared to Placebo group respectively. Blood loss >500ml was observed in 2% patients. Otherwise there were no adverse effects on mother or foetus.
Conclusion: Phloroglucinol shortens the duration of labour, is non toxic to both mother and fetus and does not cause primary post partum haemorrhage (JPMA 55:270;2005).
The problems and hazards of prolonged labour, both for the mother and foetus have been recognized for many years. The mother is exposed to high risk of infection, ketosis and obstructed labour while the foetus faces the danger of infection, asphyxia and excessive cranial moulding. O'Driscoll at the National Maternity Hospital, Dublin, introduced the concept of active management of labour and this has influenced obstetricians to change their outlook regarding the management of first stage of labour.1 Active management of labour is associated with a low incidence of prolonged labour and low cesarean section rate.2 Protraction of the first stage of labour, one of the components of prolonged labour, does not necessarily result in less than optimal uterine contractility. Its cause is multifactorial and cervix dilation is the end result of these factors. Although methods to increase uterine contractility such as amniotomy and use of oxytocics have been shown to accelerate cervical dilation, yet these methods are not without complications.3 Sedatives and belladonna Alkaloids have been tried to hasten cervical dilatation but many have adverse effects on mother and fetus.1 Spasmolytics and spasmoanalgesics mixtures are administered to facilitate dilatation of the cervix during delivery and to shorten first stage of labour.4 An ideal antispasmodic for accelerations of cervical dilations should have a prompt and long lasting action, no adverse effects on uterine contractility and be free from risk of uterine inertia. It should also have minimal side effects in the mother and foetus.5
Phloroglucinol is one of spasmolytics, primarily used for gastrointestinal tract colic.6 The drug was extensively used during 1970s and earlys 1980s for augmentation of labour. There has been a resurge of interest in the subject. To our knowledge, there has been no double blind controlled study to evaluate the routine use of this drug to accelerate labour. We evaluated its efficacy for the augmentation of labour in a randomized controlled trial keeping above mentioned points in view.
Participants and Eligibility
A randomized controlled trial was conducted in labour ward of Gynae B unit Khyber Teaching Hospital Peshawar from 1st January 2004 to 30th June 2004, to evaluate the effect of Phloroglucinol on the process of labour.
Sample size was 100 and sampling technique was convenient sampling. Inclusion criteria was labouring patients including both primigravida and multigravida, in active phase of uncomplicated labour (active phase was defined as 3 cm or > cervical dilatation with regular uterine contractions), having singleton foetus, with cephalic or breech presentations and period of gestation 34 weeks or more. Women with any obstetrical, surgical and severe medical complications such as heart disease and eclampsia, with period of gestation <34 weeks, and twin pregnancy were excluded. An informed consent obtained from all patients.
A complete history was noted and examination of patient performed. Routine investigations (FBC, urinalysis, random blood sugar, BT, CT, CTG) were performed. Fifty patients in the study group received phloroglucinol 40mg (4ml) i/v and 50 patients in the control group received placebo (distilled water) 4ml i/v at 0 hours. Dose was repeated after 60 minutes. Neither patient nor observer knew the content of the injection. Half hourly monitoring of vital signs, uterine contractions, foetal heart rate was done. Labour progress was plotted on partogram. All data pertaining to labour events, maternal and neonatal outcome, adverse effects of drug or placebo (nausea, vomiting, giddiness, palpitations, tachycardia, hypotension/ hypertension, dry mouth, blurring of vision, foetal heart rate) were recorded. Amount of blood loss after the second stage was estimated subjectively by the attending doctor and objectively by weighing the soaked pads. Blood loss of >500ml was considered abnormal. Follow up of the patients was done till 24 hours after delivery.
Three hypotheses were tested in the study. The first was that Spasmolytics like Phloroglucinol can safely reduce the duration of labour, secondly they do not have any maternal and foetal adverse effects and finally do not cause primary postpartum hemorrhage.
The primary out come measure was duration of labour. The secondary was rate of cervical dilatation, foetal outcome, any maternal side effect and effect of drug on blood loss after second stage of labour. Data was collected by the attending doctor and entered on the proforma.
Power analysis to estimate the sample size was not possible because there was no consensus on how much reduction in labour duration is of medical importance. (one of the parameters of the equation in power analysis).Therefore a sample size of 100 was taken after considering the number of patients attending the labour ward.
Patients were randomized in double blind fashion in two groups. Hundred identical paper slips (with name of drug written on 50 and placebo written on other 50) were kept in a jar. For each patient the doctor on duty picked up the slip from the jar. The slip was then numbered corresponding to serial number of the patient and kept in another jar. Neither patient nor the doctor knew the contents of the injection. During labour, patients were asked which treatment they had received (phloroglucinol or distilled water) at 3 points in time. The patients were then asked to indicate on what basis they believed the drug to be phloroglucinol or placebo.
The data was analyzed on an intention to treat. Mean (SD) and percentages were calculated. Student t-test was used to compare mean differences between two groups. The results of these two groups were analyzed for statistical significance using student t-test on SPSS version 11 and P-value <0.05 was considered significant.
Flow diagram shows flow of participants through each stage in this trial. Patients were recruited and follow up was done from1st January 2004 to 30th June 2004.
|Figure. Flow diagram shows flow of participants through each stage in this trial.|
|Table 1. Baseline characteristics of patients.|
|characteristics||Drug group(n=50)Mean (S.D.)||Placebo group(n=50)Mean (S.D.)||P -value|
|Age, Years||26.42 (6.09)||25.84 (5.38)||0.621|
|Height, cm||155.12 (3.37)||155.68 (3.06)||0.315|
|66.82 (4.52)||69.04 (3.73)||0.643|
|Period of gestation (weeks)||38.64 (1.26)||38.72 (1.35)||0.779|
|Table 2. Summary of results for Primary outcome measures.|
|Stage of Labour||Study group (min) Mean (S.D.)||Control Group (min) Mean (S.D.)||P-value|
|Active First stage (observed)||227.74 (13.60)||344.26 (9.49)||0.001|
|Second Stage||35.02 (11.93 )||45.44 (13.34)||0.001|
|Third stage||8.92 (2.52)||8.32 (2.49)||0.219|
|Total duration of labour||273.40 (25.27)||397.98 (16.25)||0.000|
|Table 3. Summary of results for Secondary outcome measures. |
Drug Group Mean (S.D.)
Control Group Mean (S.D.)
|Rate of Cervical |
Dilatation (cm/h) Fetal outcome(apgar Score)
|2.14 (0.36)||1.27 (0.36)|| |
|At 1 Minute||9.74 (0.44)||9.14 (0.77)|| |
|At 5 Minutes||9.95 (0.20)||9.80 (0.39)|| |
|Blood loss after second stage (ml)||406.59 (73.90)||428.0 (64.51)|| |
|Maternal side effects||0.00||0.00|| |
In the presented study, the duration of active 1st stage of labour was 116.52 minutes i.e. 33.62% shorter and second stage was 10.42 minutes i.e. 22.93% shorter in study group. The differences were statistically significant and the results are comparable with the studies conducted by Blasko7 and Sharma8, who reported 22% and 53% respectively decrease in the duration of 1st stage. Similar results have been reported by Himangi.1The study conducted by Hudecet4 is in discordance with our study but in that spasmolytic was used in latent phase of labour instead of the active phase. No toxic effects were noted in either mother or foetus and results are comparable with the study conducted by Ahmad5, while use of other spasmolytics are associated with side effects as reported by Sharma.8 Only 2 % patients had primary postpartum hemorrhage in our study. Similar results have been reported in the study conducted by Ahmad.5 However, Singh 3 reported 18% incidence of PPH due to uterine atony with the use of spasmolytics but they used Drotaverine hydrochloride not phloroglucinol. This incidence is statistically significant and limits the use of Drotoverine in labour. In our study 7% of patients had pregnancy induced hypertension, 2% had diabetes mellitus and 4% had previous cesarean section. Although the number of patients with these complications were not large enough but still it is suggested that phloroglucinol can be used in patients with above mentioned complications with no toxic effects and a good outcome. Further randomized controlled trials are needed to establish its efficacy in such cases as well. +In our study, all patients with <37 weeks gestation, delivered healthy babies showing that phloroglucinol can be used in patients with preterm labour without any risk of respiratory depression of foetus.
The drug appeared to have analgesic action which was an observational finding. Since majority of women were already in labour at the time of selection, calculation of exact duration of first stage of labour was not possible. The second dose of drug was given one hour after the 1st dose. Some patients may not need this and just one injection could be enough. In our study we did not segregate primigravide and multigravida while calculating the duration of labour. The drug may have different effects on both.
In conclusion, Phloroglucinol shortens the duration of labour, is non toxic to both mother and foetus and does not cause uterine atony. It also has an analgesic action. Spasmolytics as phlorogluciol have a definite role in obstetrics.
This study was approved by ethical committee of College of Physicians and Surgeons Pakistan and also by institutional local ethical committee. It was self financed.
1. Himangi S, Anahita R, Vanita S, Kumud M. The efficacy of Camylofin dihydrochlorid in acceleration of labour. A randomized double blind trial. J Bombey Hosp [serial online] 2003 july [cited 2004 july18];45(3):[1 screen] Available from: URL:http://www.bhj.org/journal/2003-4503-july/theeficacy -420.htm.
2. Bohra U, Donnelly J, O'Connell M, Geary M, Mac Quillian K, Keane DP. Active mangement of labour revisited: the first primiparous labours in 2000. J Obstet Gynaecol 2003;23:118-20.
3. Singh KC, Jain P, Goel N, Saxena A. et al. Drotaverine hydrochloride for augmentation of labour.Int J Gynaecol Obstet 2004;84:17-22.
4. Hudecek R, Nagy J, Unzeeitig V. The effect of spasmolytics on dilatation of the uterine cervix. Ceska Gynaekol 1997;62:11-14.
5. Ahmad S, Rauf B, Shafiq A. Use of Spasfan in labour. J Himont Med 2002;1:14-8.
6. Antispasmodics and anticholinergics. In: Neeshat QM. Pharmaguide, 16th edition. Karachi: Pharmaguide Publishing Company; 2003;66-70.
7. Blasko G. Mechanism of action and clinical significance of a convenient antispasmodic agent: The Physician's Update 1998;1:63-9.
8. Sharma JB, Pundir P, Kumar A, Murthy NS. Drotaverine hydrochloride vs Velethamate Bromide in acceleration of labor. Int J Gynaecol Obstet 2001;74: 255-60.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.